Physician profile
Alaa Kubbar
NPI 1528598943
$4,314.26
in general payments reported to CMS, 2019-2025
31 companies · $1,463 in 2025
The $1,463 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $184 · 2023: $1,272 · 2024: $1,395 · 2025: $1,463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,110 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,110.18 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $771.02 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $592.98 | 2022-2025 | Mounjaro, Jardiance, Humulin |
| Amgen INC. | $443.16 | 2024-2025 | Evenity, Tepezza, Prolia |
| Corcept Therapeutics | $412.43 | 2022-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $175.68 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $175.50 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $155.76 | 2023-2025 | Strensiq |
| Sequel Med Tech, LLC | $143.61 | 2025 | Twiist |
| Xeris Pharmaceuticals, INC. | $128.48 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Abbvie INC. | $119.17 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $117.95 | 2023-2024 | Farxiga |
| Kyowa Kirin, INC. | $113.24 | 2023-2025 | Crysvita |
| Novartis Pharmaceuticals Corporation | $110.57 | 2022-2025 | |
| Medtronic, INC. | $102.64 | 2022-2025 | Minimed 780g, Intellis Adaptivestim |
| Tandem Diabetes Care, INC. | $99.74 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $90.69 | 2023-2025 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.23 | 2022-2025 | Jardiance, Synjardy |
| Amneal Pharmaceuticals LLC | $73.43 | 2024-2025 | Unithroid |
| Ascendis Pharma Endocrinology INC | $52.90 | 2025 | Yorvipath |
| Madrigal Pharmaceuticals | $45.91 | 2025 | Rezdiffra |
| Esperion Therapeutics, INC. | $45.86 | 2024-2025 | Nexletol |
| Abbott Laboratories | $45.00 | 2023-2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $40.13 | 2022-2023 | Verquvo, Steglujan, Steglatro |
| Horizon Therapeutics Plc | $31.03 | 2023 | Tepezza |
| Neurocrine Biosciences, INC. | $26.72 | 2025 | |
| Chiesi USA, INC. | $25.04 | 2025 | Myalept |
| Rgh Enterprises LLC | $24.97 | 2025 | |
| Amryt Pharma Holdings LTD | $22.49 | 2022 | |
| Dexcom, INC. | $18.43 | 2023 | Dexcom G6 Transmitter |
| Beta Bionics, INC. | $17.27 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Cequr Corporation | $6.23 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alaa Kubbar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.